Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Compton Capital Management Inc. RI

Compton Capital Management Inc. RI lessened its holdings in shares of Edwards Lifesciences Co. (NYSE:EW – Get Rating) by 4.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,015 shares of the medical research company’s stock after selling 200 shares during the period. Compton Capital Management Inc. RI’s holdings in Edwards Lifesciences were worth $332,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the business. Lazard Asset Management LLC boosted its position in shares of Edwards Lifesciences by 680.2% during the 2nd quarter. Lazard Asset Management LLC now owns 50,916 shares of the medical research company’s stock worth $4,840,000 after purchasing an additional 44,390 shares during the period. Stock Yards Bank & Trust Co. purchased a new position in shares of Edwards Lifesciences during the 2nd quarter worth approximately $373,000. J.W. Cole Advisors Inc. boosted its position in shares of Edwards Lifesciences by 4.7% during the 2nd quarter. J.W. Cole Advisors Inc. now owns 3,521 shares of the medical research company’s stock worth $335,000 after purchasing an additional 157 shares during the period. Massachusetts Financial Services Co. MA boosted its position in shares of Edwards Lifesciences by 19.0% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 5,381,049 shares of the medical research company’s stock worth $511,685,000 after purchasing an additional 860,313 shares during the period. Finally, Legacy Wealth Asset Management LLC acquired a new stake in Edwards Lifesciences during the 3rd quarter worth approximately $761,000. Hedge funds and other institutional investors own 80.35% of the company’s stock.

Insiders Place Their Bets

In other news, VP Donald E. Bobo, Jr. sold 6,725 shares of the business’s stock in a transaction that occurred on Tuesday, November 8th. The shares were sold at an average price of $68.46, for a total value of $460,393.50. Following the completion of the transaction, the vice president now owns 62,561 shares of the company’s stock, valued at $4,282,926.06. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In other news, VP Daveen Chopra sold 4,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 17th. The shares were sold at an average price of $78.00, for a total value of $312,000.00. Following the completion of the transaction, the vice president now owns 18,911 shares of the company’s stock, valued at $1,475,058. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, VP Donald E. Bobo, Jr. sold 6,725 shares of the business’s stock in a transaction that occurred on Tuesday, November 8th. The shares were sold at an average price of $68.46, for a total transaction of $460,393.50. Following the completion of the transaction, the vice president now directly owns 62,561 shares of the company’s stock, valued at approximately $4,282,926.06. The disclosure for this sale can be found here. Over the last quarter, insiders sold 91,800 shares of company stock worth $6,933,324. Insiders own 1.29% of the company’s stock.

Analyst Upgrades and Downgrades

EW has been the topic of several research analyst reports. Wells Fargo & Company cut their price target on shares of Edwards Lifesciences from $121.00 to $93.00 and set an “overweight” rating on the stock in a research note on Friday, October 28th. Oppenheimer downgraded shares of Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a report on Friday, October 28th. Canaccord Genuity Group lowered their target price on shares of Edwards Lifesciences from $78.00 to $73.00 and set a “hold” rating on the stock in a report on Monday, December 12th. Cowen lowered their target price on shares of Edwards Lifesciences from $125.00 to $100.00 in a report on Friday, October 28th. Finally, Deutsche Bank Aktiengesellschaft lowered their target price on shares of Edwards Lifesciences from $113.00 to $83.00 in a report on Friday, October 28th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $91.55.

Edwards Lifesciences Price Performance

EW traded up $2.26 during midday trading on Wednesday, reaching $78.96. 2,908,866 shares of the company’s stock were exchanged, compared to its average volume of 3,119,708. The company has a debt-to-equity ratio of 0.10, a current ratio of 3.83 and a quick ratio of 3.00. The stock has a market capitalization of $48.82 billion, a PE ratio of 34.30, a P/E/G ratio of 2.64 and a beta of 1.03. The business’s 50-day moving average price is $75.84 and its 200 day moving average price is $84.36. Edwards Lifesciences Co. has a 1-year low of $67.13 and a 1-year high of $131.10.

Edwards Lifesciences (NYSE:EW – Get Rating) last announced its earnings results on Tuesday, January 31st. The medical research company reported $0.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.61 by $0.03. The company had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.33 billion. Edwards Lifesciences had a net margin of 27.20% and a return on equity of 24.75%. The firm’s quarterly revenue was up 1.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.51 earnings per share. As a group, equities analysts anticipate that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

About Edwards Lifesciences

(Get Rating)

Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart, and Critical Care. The Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques.